2. Search Result
Search Result
Pathways Recommended: NF-κB
Results for "

NF-

" in MedChemExpress (MCE) Product Catalog:

1798

Inhibitors & Agonists

11

Screening Libraries

6

Fluorescent Dye

38

Biochemical Assay Reagents

80

Peptides

23

Inhibitory Antibodies

790

Natural
Products

39

Recombinant Proteins

99

Isotope-Labeled Compounds

120

Antibodies

4

Click Chemistry

23

Oligonucleotides

3

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13982
    JSH-23
    140+ Cited Publications

    		 NF-κB Metabolic Disease Inflammation/Immunology Cancer
    JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation .
    JSH-23
  • HY-N0274
    Caffeic acid phenethyl ester
    10+ Cited Publications

    		 NF-κB Apoptosis Inflammation/Immunology Cancer
    Caffeic acid phenethyl ester is a NF-κB inhibitor.
    Caffeic acid phenethyl ester
  • HY-112461A
    NF449 octasodium
    4 Publications Verification

    		 P2X Receptor Cardiovascular Disease
    NF449 octasodium is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 octasodium is a Gsα-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs .
    NF449 octasodium
  • HY-14645
    (-)-DHMEQ
    30+ Cited Publications

    Dehydroxymethylepoxyquinomicin

    		 NF-κB Inflammation/Immunology Cancer
    (-)-DHMEQ (Dehydroxymethylepoxyquinomicin) is a potent, selective and irreversible NF-κB inhibitor that covalently binds to a cysteine residue. (-)-DHMEQ inhibits nuclear translocation of NF-κB and shows anti-inflammatory and anticancer activity .
    (-)-DHMEQ
  • HY-134476
    NF-κΒ activator 1
    10+ Cited Publications

    		 NF-κB Inflammation/Immunology
    NF-κΒ activator 1 (compound 32) is a potent NF-κΒ activator with an EC50 of 0.9 μM. NF-κΒ activator 1 induces superoxide dismutase (SOD)2 mRNA expression .
    NF-κΒ activator 1
  • HY-A0059
    Nifuratel
    3 Publications Verification

    NF 113; SAP 113; Methylmercadone

    		 Bacterial Parasite Antibiotic Fungal Apoptosis STAT Interleukin Related TNF Receptor Infection Inflammation/Immunology Cancer
    Nifuratel (NF 113) is an orally active broad-spectrum antibiotic with antiprotozoal, antibacterial, anticancer and anti-inflammatory activities, and has good inhibitory effects on Candida and Trichomonas. Nifuratel is also a STAT3 inhibitor, which significantly inhibits the growth and proliferation of human gastric cancer cells and induces apoptosis. In addition, Nifuratel also inhibits mast cell-mediated antigen hypersensitivity reactions and can be used in the study of IgE-mediated allergic diseases .
    Nifuratel
  • HY-114740
    β-Naphthoflavone
    1 Publications Verification

    5,6-Benzoflavone; beta-NF

    		 Aryl Hydrocarbon Receptor Apoptosis Neurological Disease Cancer
    β-Naphthoflavone is an exogenous aryl hydrocarbon receptor (AHR) ligand. β-Naphthoflavone can activate AHR to participate in various biological processes, including cell growth, differentiation, apoptosis, and metabolism. β-Naphthoflavone has antioxidant activity and can exert its antioxidant function by regulating the activity of antioxidant enzymes. β-Naphthoflavone is also a non-carcinogenic CYP1A inducer and can be used to study aristolochic acid (AAI) induced renal injury .
    β-Naphthoflavone
  • HY-N4187
    Licochalcone D
    5 Publications Verification

    		 NF-κB Apoptosis Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology Cancer
    Licochalcone D, a flavonoid compound mainly existing in the root of Glycyrrhiza uralensis, is a potent and orally active inhibitor of NF-kappaB (NF-κB) p65. Licochalcone D possesses antioxidant, anti-inflammatory, anti-cancer properties .
    Licochalcone D
  • HY-P0151
    SN50
    Maximum Cited Publications
    44 Publications Verification

    		 NF-κB Inflammation/Immunology
    SN50 is a cell permeable inhibitor of NF-κB translocation.
    SN50
  • HY-134477
    NF-κΒ activator 2
    5 Publications Verification

    		 NF-κB Neurological Disease
    NF-κΒ activator 2 is a potent and orally active NF- B activator, with an EC50 of 1.58 μM. NF-κΒ activator 2 induces SOD2 through increasing NF- B expression and activation. NF-κΒ activator 2 can be used for the research of amyotrophic lateral sclerosis (ALS) .
    NF-κΒ activator 2
  • HY-130246
    NF-56-EJ40
    10+ Cited Publications

    		 Succinate Receptor 1 Inflammation/Immunology
    NF-56-EJ40 is a potent, high-affinity, and highly selective human SUCNR1 (GPR91) antagonist with an IC50 of 25 nM and a Ki of 33 nM, and shows almost no activity towards rat SUCNR1. NF-56-EJ40 has high affinity for humanized rat SUCNR1 with a Ki value of 17.4 nM .
    NF-56-EJ40
  • HY-N0277
    Aconine
    2 Publications Verification

    Jesaconine

    		 NF-κB Inflammation/Immunology Cancer
    Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced NF-κB activation.
    Aconine
  • HY-D0976
    NF279
    1 Publications Verification

    		 P2X Receptor HIV NTPDase CXCR Infection
    NF279 is a selective P2X1 receptor antagonist and NTPDase inhibitor, with a P2X1 IC50 value of 19 nM. NF279 suppresses GABA-evoked currents, reduces ATP-excited respiratory activity, alters hypoglossal nerve burst parameters, and blocks CXCR4, CCR5, CXCR3, and CXCR7-mediated calcium responses. NF279 arrests HIV-1 fusion downstream of CD4 binding, inhibits R5- and X4-tropic HIV-1 strains. NF279 can be used for the research of HIV-1 infection .
    NF279
  • HY-108672
    NF157

    		P2Y Receptor Inflammation/Immunology
    NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively . NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA) .
    NF157
  • HY-161719
    NF764
    1 Publications Verification

    		 β-catenin Cancer
    NF764 is a potent β-catenin (CTNNB1) degrader. NF764 reduces CTNNB1 protein levels in a proteasome-dependent manner. NF764 can be used in the study of cancer .
    NF764
  • HY-155998
    NF-κB-IN-11
    1 Publications Verification

    		 NF-κB Inflammation/Immunology
    NF-κB-IN-11 (Compound 3i) is a NF-κB inhibitor. NF-κB-IN-11 inhibits TNF-α induced activation of NF-κB pathway, and inhibits nuclear translocation of NF-κB. NF-κB-IN-11 down-regulates the expression levels of phosphor-IKK, IκBα, and NF-κB p65. NF-κB-IN-11 has anti-inflammatory activity, and alleviates dextran sulfate sodium-induced colitis in mice. NF-κB-IN-11 (p.o.) shows a MTD more than 1852 mg/kg in mice acute toxicity assay .
    NF-κB-IN-11
  • HY-138537
    NF-κB-IN-1
    3 Publications Verification

    		 IKK Cancer
    NF-κB-IN-1, a 4-arylidene crucumin analogue, is a potent NF-κB signaling pathway inhibitor. NF-κB-IN-1 directly inhibits IKK to block NF-κB activation. NF-κB-IN-1 effectively inhibits the viability of lung cancer cells and attenuates the clonogenic activity of A549 cells .
    NF-κB-IN-1
  • HY-112461
    NF449

    		P2X Receptor Cardiovascular Disease
    NF449 is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 is a Gsα-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs .
    NF449
  • HY-174138
    NF-κB degrader 1

    		NF-κB Inflammation/Immunology
    NF-κB degrader 1 (Compound MD-1) is a NF-κB1 p105 subunit degrader. NF-κB degrader 1 shows anti-inflammatory activity (IC50 for inhibiting TNF-α is 2.02 μM, and for inhibiting NO is 5.40 μM). NF-κB degrader 1 induces p105 degradation dependent on the Cullin-RING ligase (CRL) SCFBTCP, suppressing NF-κB transcriptional activity. NF-κB degrader 1 is promising for research of inflammation-related diseases .
    NF-κB degrader 1
  • HY-133987
    AP-1/NF-κB activation inhibitor 1
    3 Publications Verification

    		 NF-κB Inflammation/Immunology
    AP-1/NF-κB activation inhibitor 1 is a potent AP-1 and NF-κB mediated transcriptional activation inhibitor (IC50=1 μM), without blocking basal transcription driven by the β-actin promoter. AP-1/NF-κB activation inhibitor 1 has a similar inhibitory effect on the production of IL-2 and IL-8 levels in stimulated cells .
    AP-1/NF-κB activation inhibitor 1
  • HY-108659
    NF340

    		P2Y Receptor Inflammation/Immunology
    NF340 is a P2Y11 receptor inhibitor with a pIC50 of 7.3-7.7 against human P2Y11 receptor, and it exhibits high selectivity over other P2Y family receptors. NF340 binds to the ATP-binding amino acid residues of the P2Y11 receptor to inhibit its activity, block nociceptive activity, and reduce spinal dorsal horn P2Y11 receptor upregulation induced by spinal cord injury. NF340 attenuates the NFκB signaling pathway activated by IL-1β by decreasing IκBα phosphorylation, nuclear p65 accumulation and NFκB promoter activity. NF340 inhibits IL-1β-induced pro-inflammatory cytokine expression, reduces intracellular ROS and 4-HNE levels, and suppresses IL-1β-induced matrix metalloproteinase expression in primary fibroblast-like synoviocytes. NF340 inhibits ATP-induced elevation of intracellular calcium 2+ concentration and cell migration in human hepatocellular carcinoma cells. NF340 is applicable to the research of neuropathic pain, myocardial ischemia/reperfusion injury, inflammatory pain, rheumatoid arthritis and hepatocellular carcinoma .
    NF340
  • HY-147972
    NF-κB/MAPK-IN-1

    		NF-κB p38 MAPK NO Synthase COX Inflammation/Immunology
    NF-κB/MAPK-IN-1 (compound 11a) is a potent inhibitor of NF-κB and MAPK pathway. NF-κB/MAPK-IN-1 shows inhibitory activity against NO production, with an IC50 of 6.96 µM. NF-κB/MAPK-IN-1 suppresses LPS-induced iNOS, COX-2, ERΚ and P38 signaling activation. NF-κB/MAPK-IN-1 can prevent LPS induced inflammatory response in macrophages. NF-κB/MAPK-IN-1 can be used for rheumatoid arthritis (RA) research .
    NF-κB/MAPK-IN-1
  • HY-130256
    β-NF-JQ1

    		PROTACs Epigenetic Reader Domain Cancer
    β-NF-JQ1 is a PROTAC that recruits Aryl Hydrocarbon Receptor E3 ligase to target proteins. β-NF-JQ1 is directed against bromodomain-containing (BRD) proteins using β-NF as an AhR ligand, induces the interaction of AhR and BRD proteins, and displays effective anticancer activity that correlated with protein knockdown activity .
    β-NF-JQ1
  • HY-108676
    NF023 hexasodium
    1 Publications Verification

    		 P2X Receptor Neurological Disease
    NF023 hexasodium is a selective and competitive P2X1 receptor antagonist, with IC50 values of 0.21 μM, 28.9 μM, > 50 μM and > 100 μM for human P2X1, P2X3, P2X2, and P2X4-mediated responses respectively .
    NF023 hexasodium
  • HY-144765
    NF-κB-IN-4
    1 Publications Verification

    		 NF-κB Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    NF-κB-IN-4 (compound 17) is a potent NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .
    NF-κB-IN-4
  • HY-168710
    TLR4/NF-κB-IN-1

    		Toll-like Receptor (TLR) NF-κB IKK Inflammation/Immunology
    TLR4/NF-κB-IN-1 (Compound 7x) is an orally available inhibitor that specifically targets the TLR4/NF-κB signaling pathway, offering anti-inflammatory effects and the ability to cross the blood-brain barrier. TLR4/NF-κB-IN-1 can reduce acute neuroinflammation in mice caused by LPS (HY-D1056) and downregulate the expression of TLR4, P-NF-κB and P-IκB-α proteins .
    TLR4/NF-κB-IN-1
  • HY-ER013J
    Sodium carbonate, anhydrous, meets analytical specification of Ep,BP,JP,NF

    		Biochemical Assay Reagents Others
    Sodium carbonate, anhydrous, meets analytical specification of Ep, BP, JP, NF is a biochemical reagent and a buffer component.
    Sodium carbonate, anhydrous, meets analytical specification of Ep,BP,JP,NF
  • HY-P1832A
    PTD-p65-P1 Peptide TFA
    3 Publications Verification

    		 NF-κB Apoptosis Inflammation/Immunology Cancer
    PTD-p65-P1 Peptide TFA is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis .
    PTD-p65-P1 Peptide TFA
  • HY-108661A
    NF546 hydrate

    		P2Y Receptor Inflammation/Immunology
    NF546 (hydrate) is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 (hydrate) stimulates release of interleukin-8 from human monocyte-derived dendritic cells .
    NF546 hydrate
  • HY-130246A
    NF-56-EJ40 hydrochloride
    10+ Cited Publications

    		 Succinate Receptor 1 Inflammation/Immunology
    NF-56-EJ40 hydrochloride is a potent, high-affinity, and highly selective human SUCNR1 (GPR91) antagonist with an IC50 of 25 nM and a Ki of 33 nM, and shows almost no activity towards rat SUCNR1. NF-56-EJ40 hydrochloride has high affinity for humanized rat SUCNR1 with a Ki value of 17.4 nM .
    NF-56-EJ40 hydrochloride
  • HY-ER013I
    Sodium carbonate anhydrous, meets analytical specification of Ph. Eur., BP, NF, FCC, E500

    Calcined soda meets analytical specification of Ph. Eur., BP, NF, FCC, E500

    		 Biochemical Assay Reagents Neurological Disease
    Sodium carbonate anhydrous, meets analytical specification of Ph. Eur., BP, NF, FCC, E500 is a biochemical assay reagent suitable for buffer configuration .
    Sodium carbonate anhydrous, meets analytical specification of Ph. Eur., BP, NF, FCC, E500
  • HY-P991665
    MEN1112

    OBT357NF; OBT357

    		 Transmembrane Glycoprotein Cancer
    MEN1112 (OBT357NF) is a selective humanized monoclonal antibody targeting the Bst1/CD157 antigen (EC50=1 nM). MEN1112 exerts potent antitumor activity against acute myeloid leukemia (AML) cells. MEN1112 is promising for research of hematological malignancies such as AML .
    MEN1112
  • HY-Y0332L
    Potassium dihydrogen phosphate, meets analytical specification of Ph. Eur., NF, E340

    Potassium phosphate monobasic, meets analytical specification of Ph. Eur., NF, E340

    		 Biochemical Assay Reagents NF-κB Others
    Potassium dihydrogen phosphate (Potassium phosphate monobasic), meeting the analytical specifications of Ph. Eur., NF, E340, is a reagent with buffering capacity, used for preparing biological buffers. Potassium dihydrogen phosphate downregulates the expression of IκBα in the cytoplasm, increases the expression of p-P65 in the cytoplasm, and upregulates the expression of P65 in the nucleus, thereby activating the NF-κB pathway. Potassium dihydrogen phosphate promotes the proliferation of human periodontal ligament stem cells in the logarithmic growth phase. Potassium dihydrogen phosphate upregulates the expression of odontogenic/osteogenic markers (OCN, DSP/DSPP, OSX, RUNX2, ALP) in human periodontal ligament stem cells and enhances the mineralization capacity of these cells. Potassium dihydrogen phosphate can be used in the research of periodontal diseases .
    Potassium dihydrogen phosphate, meets analytical specification of Ph. Eur., NF, E340
  • HY-168482
    NF-κB/MAPK-IN-2

    		NF-κB p38 MAPK Cancer
    NF-κB/MAPK-IN-2 (compound 14) is a potent NF-κB and MAPK Inhibitor. NF-κB/MAPK-IN-2 decreases the protein expression of p-p65, p-IκB, p-p38, p-JNK, and p-ERK. NF-κB/MAPK-IN-2 reduces the LPS-induced release of TNF-α and IL-6. NF-κB/MAPK-IN-2 inhibits nuclear translocation of p65 and c-Fos. NF-κB/MAPK-IN-2 has the potential for the research of sepsis .
    NF-κB/MAPK-IN-2
  • HY-101660
    Nifursemizone

    Etafurazone; NF161

    		 Parasite Infection
    Nifursemizone is an antiprotozoal agent.
    Nifursemizone
  • HY-19498
    WAY-204688

    SIM-688

    		 NF-κB Inflammation/Immunology
    WAY-204688 is an estrogen receptor (ER-α) selective, orally active inhibitor of NF-κB transcriptional activity with an IC50 of 122 ± 30 nM for NF-κB-luciferase (NF-κB-luc) in HAECT-1 cells.
    WAY-204688
  • HY-N0276
    Flaconitine

    Acetylaconitine; 3-Acetylaconitine

    		 NF-κB Neurological Disease Cancer
    Flaconitine is considered to be a NF-κB inhibitor.
    Flaconitine
  • HY-177624
    Cupabimod

    AMG0103

    		 NF-κB Inflammation/Immunology
    Cupabimod is a decoy oligodeoxynucleotide for transcription factor NF-κB.
    Cupabimod
  • HY-144744
    NF-κB-IN-3

    		NF-κB Cancer
    NF-κB-IN-3 (Compound 2) is a NF-κB inhibitor with an IC50 of 0.70 µM. NF-κB-IN-3 can be used as an antitumor agent .
    NF-κB-IN-3
  • HY-108661
    NF546

    		P2Y Receptor Inflammation/Immunology
    NF546 is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 stimulates release of interleukin-8 from human monocyte-derived dendritic cells .
    NF546
  • HY-N12283
    NF-κB-IN-13

    		NF-κB Inflammation/Immunology
    NF-κB-IN-13 (compound 12) can significantly inhibit LPS-induced NF-κB activation and NO production in RAW264.7 macrophages. NF-κB-IN-13 has anti-inflammatory effects .
    NF-κB-IN-13
  • HY-175833
    NF-κB-IN-20

    		NF-κB Keap1-Nrf2 Heme Oxygenase (HO) Interleukin Related TNF Receptor Reactive Oxygen Species (ROS) SOD Inflammation/Immunology
    NF-κB-IN-20 is an orally active NF-κB inhibitor. NF-κB-IN-20 directly binds to the Keap1 protein, activating the Keap1/Nrf2/HO-1 antioxidant pathway, and simultaneously inhibiting the NF-κB inflammatory pathway, thereby synergistically reducing oxidative stress and inflammatory responses. NF-κB-IN-20 M11 inhibits the expression of IL-6, IL-1β, and TNF-α, significantly reduces the level of ROS, and restores the mitochondrial membrane potential. NF-κB-IN-20 can be used for the study of acute lung injury (ALI) .
    NF-κB-IN-20
  • HY-108671
    NF110

    		P2X Receptor Neurological Disease
    NF110 is a P2X3 receptor antagonist (Ki = 36 nM) and inactive toward P2Y receptors stably expressed (IC50s > 10 M). NF110 blocks alphabeta-methylene-ATP-induced currents (IC50 = 527 nM) in rat dorsal root ganglia neurons .
    NF110
  • HY-146058
    NF-κB/PON1-IN-1

    		NF-κB Reactive Oxygen Species (ROS) Cancer
    NF-κB/PON1-IN-1 (Compound 16) is a NF-κB/PON1 pathway inhibitor. NF-κB/PON1-IN-1 has antioxidant (IC50 = 45.76 µM) and hepatoprotective activities .
    NF-κB/PON1-IN-1
  • HY-175227
    STAT3/NF-κB-IN-1

    		STAT NF-κB Apoptosis Caspase Bcl-2 Family Cancer
    STAT3/NF-κB-IN-1 is a potentSTAT3 and NF-κB inhibitor with IC50s of 5.86 (STAT3) and 4.22 μM (NF-κB) in 4T1 cells. STAT3/NF-κB-IN-1 is able to induce apoptosis via its upregulation on key apoptotic regulators; caspases-3/9, Bax and downregulation of Bcl-2. STAT3/NF-κB-IN-1 exerts considerable anticancer activity against breast cancer cell lines and reduces tumor volume in vivo. STAT3/NF-κB-IN-1 can be used for the study of breast cancer .
    STAT3/NF-κB-IN-1
  • HY-N16422
    Mer-NF5003E

    		HIV HIV Protease Infection
    Mer-NF5003E is a non-nucleoside reverse transcriptase inhibitor targeting HIV-1 reverse transcriptase (RT) (EC50=50 μM). Mer-NF5003E exhibits inhibitory activity against wild-type HIV-1 and multiple NNRTI-resistant strains (e.g., K103N, Y181C). Mer-NF5003E is promising for research of HIV infections .
    Mer-NF5003E
  • HY-A0059R
    Nifuratel (Standard)

    NF 113 (Standard); SAP 113 (Standard); Methylmercadone (Standard)

    		 Reference Standards Bacterial Parasite Antibiotic Infection
    Nifuratel (Standard) is the analytical standard of Nifuratel. This product is intended for research and analytical applications. Nifuratel (NF 113, SAP 113) is a broad-spectrum antibiotic with activity against bacteria, fungi and trichomonas.
    Nifuratel (Standard)
  • HY-P1832
    PTD-p65-P1 Peptide

    		NF-κB Apoptosis Inflammation/Immunology Cancer
    PTD-p65-P1 Peptide is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis .
    PTD-p65-P1 Peptide
  • HY-123915
    Antimalarial agent 20

    		Parasite Infection
    Antimalarial agent 20 (Compound 49c) is an antimalarial agent with an IC50 of 0.6 nM against P. falciparum NF54 parasite strain in the NF54 albumax assay .
    Antimalarial agent 20
  • HY-177624A
    Cupabimod sodium

    AMG0103 sodium

    		 NF-κB Inflammation/Immunology
    Cupabimod sodium is a decoy oligodeoxynucleotide for transcription factor NF-κB.
    Cupabimod sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: